EW
Edwards Lifesciences (NYSE: EW) reported stronger-than-expected sales growth of 12.
Article Summary
BUY- Edwards Lifesciences (NYSE: EW) reported stronger-than-expected sales growth of 12.5% as Edwards Lifesciences continues investing in structural heart therapies and expanding adoption globally.
- TAVR sales grew 11.3% year-over-year to $1.3 billion, with procedural growth driven by sustained clinical momentum and evidence supporting proactive severe aortic stenosis management.
- Treatment decisions continued to be shaped by long-term differentiation of the SAPIEN platform, with a new PARTNER 3 trial sub-analysis at 7 years reinforcing the best-in-class valve performance and durability data presented at the recent New York Valves conference.
- Growth benefitted from the exit of a competitor in Q2 2025 and compelling S APIEN durability data, while average selling prices remained stable globally.
- CEO Bernard Zovighian reaffirmed confidence in the company's target of approximately 10% total company sales growth over the longer term.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 13.8% | 25% | 50.0 ptsMeets Minimum (13.8%) - Passes screener |
| EPS Growth Next 5Y ? | 13.8% | 25% | 35.0 ptsBelow Screener (13.8%) - Modest outlook |
| Target Price Upside ? | 19.3% | 20% | 60.0 ptsModerate Upside (19.3%) - Target: $100.03 vs Current: $83.82 |
| Gross Margin % ? | 78.0% | 15% | 100.0 ptsExceptional (78.0%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -13.0% | 15% | 40.0 ptsMild Pullback (-13.0%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About EW
- Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
- It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.
- The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve.
- It distributes its products through a direct sales force and independent distributors.
- Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.